GenomOncology Announces Collaborations, Partnerships Before AGBT
February 12, 2014
By Bio-IT World Staff
February 12, 2014 | GenomOncology, based in Westlake, Ohio, has developed the GO Clinical Workbench, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the molecular profile of each patient’s tumor genome into an actionable clinical report. The research platform, GenomAnalytics, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants.
The company’s Board of Directors includes Manuel J. Glynias, President and CEO of GenomOncology, Bradley Wertz, former President and COO of Rosetta, John Doulis, CIO of a TriStar Technology Ventures partner fund, and Lee Zapis, principal of Zapis Capital Group.
The company will be attending and presenting at the AGBT meeting in Marco Island, Florida starting today and has primed the pump for their appearance with a string of press releases over the past two weeks.
The company announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations. GenomOncology and RPCI are working together to develop a software platform that integrates laboratory information management systems, electronic health records, information technology and bioinformatics and that provides a workflow enabling genomic analysts and pathologists to create actionable reports.
GenomOncology and Vanderbilt-Ingram Cancer Center (VICC) are working together on the exclusive commercial development of a decision support tool based on My Cancer Genome, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers. The MyCancerGenome.org website will remain free and open to the public. In addition, GenomOncology will develop a decision support tool based on My Cancer Genome data that will enable automated interpretation of mutations in the genome of a patient’s tumor, providing actionable results in hours versus days. According to the terms of the agreement, all commercial use of My Cancer Genome in any form will be licensed through GenomOncology.
The University of Pittsburgh has selected GenomOncology’s GenomAnalytics platform and services to explore and mine the breadth of data that exists in The Cancer Genome Atlas (TCGA). The University of Pittsburg is one of the largest contributors to TCGA, and the GenomAnalytics platform will be used to investigate and visualize cancer genomic research data as a part of the University’s Personalized Medicine research initiative. The project is intended to engage the cancer research community and leverage the GenomAnlaytics platform to develop, validate and review scientific hypotheses associated with the unique drivers associated with cancer.
CompanionDx has selected GenomOncology’s GO Clinical Workbench to launch a series of next generation sequencing (NGS)-based assays related to cancer. CompanionDx will leverage GenomOncology’s GO Clinical Workbench to manage the entire workflow: from raw sequencing data through delivery of an actionable clinical report to the client.